Core Viewpoint - The company emphasizes its commitment to fulfilling social responsibilities sustainably while providing quality pharmaceuticals and health services to more patients in alignment with national policies and local needs [1]. Group 1 - The company acknowledges its role as a listed entity in meeting social responsibilities [1]. - Future efforts will focus on integrating national policy directions with local actual needs [1]. - The aim is to ensure that quality medicines and professional health services benefit a larger patient base [1].

Market Overview - The A-share market exhibited a fluctuating and differentiated pattern last week, with major indices showing mixed performance and active rotation among hot sectors [1][7] - Institutions generally hold an optimistic outlook, believing the market is likely to trend upward [1][7] - As of January 25, over 950 companies have disclosed their 2025 earnings forecasts, with around 40% of these companies showing positive performance [1][7] Semiconductor Industry - The semiconductor industry, particularly companies related to artificial intelligence, data center construction, and domestic substitution, is expected to see strong earnings growth in 2025 [1][8] - Notable companies include: - Zhongwei Semiconductor expects revenue of approximately 1.122 billion yuan, a year-on-year increase of about 23%, and a net profit of 284 million yuan, up approximately 107% [8] - Juchip Technology anticipates revenue of 922 million yuan, a 41.44% increase, and a net profit of 204 million yuan, up 91.40% [2] - Baiwei Storage forecasts revenue between 10 billion to 12 billion yuan, a growth of 49.36% to 79.23%, and a net profit of 850 million to 1 billion yuan, a staggering increase of 427.19% to 520.22% [3][9] Pharmaceutical Industry - The pharmaceutical sector is experiencing a "polarized" performance, with over 60 companies disclosing earnings forecasts, about half of which are positive [1][9] - Key performers include: - Zhaoyan New Drug expects a net profit of approximately 233 million to 349 million yuan, a year-on-year increase of 214% to 371% [10] - Shanghai Yizhong anticipates a net profit of 6 million to 7 million yuan, a growth of 760.18% to 903.54% [10] - However, companies like Zhifei Biological are projected to incur significant losses, with an expected net loss of 10.7 billion to 13.7 billion yuan [10][5] Banking Sector - As of January 25, eight listed banks have released earnings reports, with all showing year-on-year growth in net profit [5][11] - Key statistics include: - China Merchants Bank's total assets surpassing 13 trillion yuan, and Industrial Bank exceeding 11 trillion yuan [11] - The highest net profit growth among these banks is from Hangzhou Bank at 12.05%, followed by Shanghai Pudong Development Bank at 10.52% [11] - The growth drivers for banks include improved cost of liabilities and rapid growth in intermediary business income, with Ningbo Bank's net income from fees and commissions increasing by 30.72% [12]

资料显示，天津市三鱼诊所有限公司成立于2026年1月26日，法定代表人为马刚，注册资本100万人民 币，公司位于天津市，诊所服务、中医诊所服务（须在中医主管部门备案后方可从事经营活动）、保健 食品（预包装）销售、食品销售（仅销售预包装食品）、第二类医疗器械销售、第一类医疗器械销售、 企业管理咨询、市场营销策划、健康咨询服务（不含诊疗服务）、中医养生保健服务（非医疗）、卫生 用品和一次性使用医疗用品销售、病人陪护服务、康复辅具适配服务、家政服务、养生保健服务（非医 疗）、会议及展览服务（出国办展须经相关部门审批）、互联网销售（除销售需要许可的商品）。（除 依法须经批准的项目外，凭营业执照依法自主开展经营活动）许可项目：医疗服务、药品零售、第三类 医疗器械经营、药品类易制毒化学品销售、依托实体医院的互联网医院服务、药品互联网信息服务、医 疗器械互联网信息服务。（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目 以相关部门批准文件或许可证件为准）。 天眼查工商信息显示，近日，天津力生制药股份有限公司出资100万元成立天津市三鱼诊所有限公司， 持股100%，所属行业为卫生。 来源：市场资讯 ...

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 1.本次回购注销的限制性股票授予日为2022年12月27日，本次回购注销限制性股票数 量共计30,016股，占回购前公司总股本257,616,859股的0.0117%，回购价格为8.76元/股。 2.截至2026年1月27日，上述限制性股票已在中国证券登记结算有限责任公司深圳分公 司办理完回购注销相关手续。 证券代码：002393 证券简称：力生制药 公告编号：2026-006 天津力生制药股份有限公司 关于部分限制性股票回购注销完成暨股份变动的公告 4.2022年11月15日，公司于巨潮资讯网（www.cninfo.com.cn）上披露了《监事会关于 公司2022年限制性股票激励计划授予激励对象名单的公示情况说明及核查意见》（公告编 号：2022-074）。 5.2022年12月5日，公司召开2022年第五次临时股东大会，审议并通过了《关于公司 2022年限制性股票激励计划（草案）及其摘要的提案》《关于公司2022年限制性股票激励 1 计划实施考核管理办法的提案》以及《关于提请公司股东大会授权董事会 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 ■ 二、与会计师事务所沟通情况 证券代码：002393 证券简称：力生制药 公告编号：2026-005 天津力生制药股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日-2025年12月31日 2、预计的业绩： √同向上升 3、业绩预告为区间 本次业绩预告相关数据是公司财务部门初步测算的结果，未经会计师事务所审计。公司已就业绩预告有 关事项与年报审计会计师事务所进行了预沟通，公司与会计师事务所在本报告期的业绩预告方面不存在 分歧。 三、业绩变动原因说明 报告期内，公司持续加大市场拓展力度，产品销售有所提升；加之天士力生物医药产业集团有限公司分 红因素影响，归属于上市公司股东的净利润同比增幅较大。 四、其他相关说明 本次业绩预告是公司财务部门初步核算的结果，具体财务数据以公司披露的2025年度报告为准。敬请广 大投资者审慎决策，注意投资风险。 特此公告。 天津力生制药股份有限公司 董事会 2026年01月24日 ...

Group 1 - JunDa Co., Ltd. announced that the comprehensive cost-effectiveness of perovskite photovoltaic technology in extreme space environments remains to be verified [2][5] - The company has invested 30 million yuan to acquire a 16.67% stake in Starwing Chip Energy, but no formal business agreement has been signed for space photovoltaic projects [2][5] - The technology shows potential advantages in lightweight, low cost, and high radiation resistance, but long-term reliability and cost-effectiveness in space are still uncertain [2][5] Group 2 - Aotewei stated that the "space photovoltaic" sector is still in the early exploration and research phase, with significant uncertainties in the industrialization process [3] - The company emphasized that product development to commercial application requires a considerable period, and the impact of related positive expectations on actual operating performance is highly uncertain [3] Group 3 - Tongyu Communications announced its participation in the A1 round financing of Beijing Blue Arrow Hongqing Technology, investing 30 million yuan for a 1.8293% stake [3] - The company will transition from direct to indirect ownership of Hongqing Technology through a partnership agreement [3] Group 4 - Huajin Technology received approval from the China Securities Regulatory Commission for the issuance of H-shares, planning to issue up to 101,573,100 shares [4] - Trina Solar announced a change in the use of remaining raised funds, reallocating 1.7 billion yuan to a new project for distributed smart photovoltaic power station construction [4][5] Group 5 - Yunnan City Investment plans to publicly transfer a 10.5% stake in Qicai Company with a base price of 293 million yuan [6] - Zijin Mining announced the completion of the second phase of the Giant Dragon Copper Mine, increasing production capacity to 350,000 tons per day [6] Group 6 - Shuaifeng Electric expects a net profit loss of 43 million to 62 million yuan in 2025, with potential delisting risk warnings for its stock [7] - Anqi Yeast plans to invest 222 million yuan in a green manufacturing project for yeast products with an annual output of 12,000 tons [7] Group 7 - Zhengzhou Coal and Electricity announced the cessation of production at the Chaohua Coal Mine due to resource depletion and safety risks, expecting a 311 million yuan impairment loss [8] - Oujing Technology announced partial production line shutdowns at its subsidiaries to reduce losses and operating costs [8] Group 8 - North Car Blue Valley plans to invest in the construction of a high-end platform model industrialization and digital upgrade project with a total investment of 1.991 billion yuan [9] - Jingzhida signed a significant contract worth 1.311 billion yuan for semiconductor testing equipment [9] Group 9 - Yanghe Co. announced a cash dividend plan for 2025-2027, committing to distribute no less than 100% of net profit each year [10] - Yanghe Co. also projected a net profit decline of 62.18% to 68.30% for 2025 due to market adjustments and increased channel inventory [10] Group 10 - Huitong Energy expects a net profit decrease of 69.51% to 75.82% for 2025, primarily due to the absence of non-recurring income from property relocation rewards [11] - Dahua Co. reported a net profit increase of 32.65% for 2025, driven by business optimization and cost control [12] Group 11 - Hangzhou Bank reported a net profit increase of 12.05% for 2025, maintaining a stable non-performing loan ratio [12] - Aotejia expects a net profit increase of 41.85% to 79.67% for 2025, supported by sales growth and cost control measures [12] Group 12 - Shenke Co. anticipates a net profit increase of 65.75% to 98.9% for 2025, benefiting from overseas strategy and revenue growth [13] - Pioneering Technology expects a net profit increase of 50.82% to 109.21% for 2025, driven by product technology iterations and market expansion [13] Group 13 - Shanchuang Technology expects a net profit increase of 81.77% to 134.78% for 2025, fueled by demand for enterprise-level storage products [14] - Anshuo Information anticipates a net profit increase of 52.44% to 98.83% for 2025, with government subsidies contributing to the growth [14] Group 14 - Zhongwei Company expects a net profit increase of 28.74% to 34.93% for 2025, driven by increased customer recognition of its plasma etching equipment [15] - Jingfang Technology anticipates a net profit increase of 44.41% to 52.32% for 2025, benefiting from the automotive industry's growth [16] Group 15 - Fuda Alloy expects a net profit increase of 119.14% to 219.95% for 2025, driven by strong demand in emerging applications [17] - Feirongda anticipates a net profit increase of 57.23% to 83.43% for 2025, supported by stable growth in communication and cooling business [17] Group 16 - Licheng Performing Arts expects a net profit decrease of 12.75% to 32.21% for 2025, impacted by regional travel environment fluctuations [22] - Lisheng Pharmaceutical anticipates a net profit increase of 116.77% to 138.44% for 2025, driven by market expansion and product sales [23] Group 17 - JMC reported a net profit decrease of 22.71% for 2025, despite a 2.07% increase in total revenue [27] - Daoshi Technology expects a net profit increase of 206.01% to 269.76% for 2025, driven by overseas business expansion [28] Group 18 - Jin Kai New Energy plans to repurchase shares worth 500 million to 600 million yuan, with a maximum repurchase price of 7.5 yuan per share [29] - Longyun Co. announced a stock suspension due to plans to acquire a 58% stake in Yuheng Film Industry [30]

力生制药表示，报告期内，公司持续加大市场拓展力度，产品销售有所提升；加之天士力生物医药产业 集团有限公司分红因素影响，归属净利润同比增幅较大。 北京商报讯（记者 丁宁）1月23日晚间，力生制药（002393）发布2025年业绩预告显示，预计2025年实 现归属净利润4亿元至4.4亿元，同比增长116.77%-138.44%。 ...

Market Performance - The three major A-share indices collectively rose on January 23, with over 3,900 stocks closing higher, including 121 stocks hitting the daily limit up [1] - For the week, the Shanghai Composite Index increased by 0.83%, the Shenzhen Component Index rose by 1.11%, while the ChiNext Index fell by 0.34% [2] Weekly Stock Performance - Over 4,200 stocks rose this week, with 35 stocks gaining over 30%. The largest increase was seen in *ST Lifan, which surged by 95.52% [3] - Other notable gainers included *ST K Pharmaceutical and Fenglong Co., which both saw increases exceeding 50% [3] - The power equipment sector had 10 stocks listed among those with over 30% gains, while the machinery and non-ferrous metals sectors had 4 stocks each [3] Top Gainers - The top gainers for the week included: - *ST Lifan: 95.52% increase, closing at 1.31 yuan [4] - *ST K Pharmaceutical: 70.37% increase, closing at 0.92 yuan [4] - Fenglong Co.: 61.08% increase, closing at 99.53 yuan [4] - Other significant gainers included companies in construction decoration and power equipment sectors [4] Weekly Decliners - Among the stocks that declined, 46 stocks fell by over 10%, with Koma Materials dropping over 30% [5] - Other notable decliners included Silin Jie and Bofei Electric, which saw declines of over 24% [5] Institutional Activity - Institutions were active in the market, with 160 stocks appearing on the institutional leaderboard, net buying 102 stocks and net selling 58 stocks [7] - The highest net buying was seen in Shengxin Lithium Energy, which rose by 26.38% with a net institutional purchase of approximately 638.55 million yuan [9] - Other stocks with significant institutional net buying included Quanfeng Technology and Hunan Silver, with net purchases of 604.81 million yuan and 352.97 million yuan, respectively [9] Notable Announcements - Shuaifeng Electric announced an expected net loss of 43 million to 62 million yuan for 2025, with projected revenue between 210 million to 250 million yuan [12] - Anqi Yeast plans to invest 222 million yuan in a new green manufacturing project for yeast products [13] - Construction Machinery expects a net loss of approximately 2.072 billion yuan for 2025, attributed to a downturn in the tower crane rental market [13] - Aerospace Electric anticipates a net loss of 39 million to 58 million yuan for 2025, impacted by industry overcapacity and competitive pressures [13] - Lisheng Pharmaceutical forecasts a net profit of 400 million to 440 million yuan for 2025, representing a year-on-year increase of 116.77% to 138.44% [14]

力生制药（002393）(002393.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润4亿元 至4.4亿元，同比增长116.77%-138.44%;扣除非经常性损益后的净利润1.6亿元至1.9亿元，同比增长 55.34%-84.47%。 ...

智通财经APP讯，力生制药(002393.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润 4亿元至4.4亿元，同比增长116.77%-138.44%;扣除非经常性损益后的净利润1.6亿元至1.9亿元，同比增长 55.34%-84.47%。 ...